Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Precision Biologics, Inc
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03476681CT.gov Study of NEO-201 in Solid Tumors Expansion Cohorts | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uterine Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Monoclonal Antibody Neo-201 (this asset) | Precision Biologics, Inc | P1/2 | CC · 47 |
| GALFER | Sunnybrook Health Sciences Centre | P4 | BB |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Gynecologic Oncology Associates | P4 | BB |
| Marcaine | University of California, Irvine | P3 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Sirexatamab | Leap Therapeutics, Inc. | P2 | B |
| Gemogenovatucel-T | Gradalis, Inc. | P2 | B |
| Durvalumab | Mary Crowley Medical Research Center | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
+42 more in the Uterine Cancer cohort
Other indications for Monoclonal Antibody Neo-201
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1/2 | CC · 41 |
| Head And Neck Squamous Cell Carcinoma | — | P1/2 | CC · 41 |
| Cervical Cancer | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GALFERSunnybrook Health Sciences CentreBB
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Gynecologic Oncology AssociatesBB
- MarcaineUniversity of California, IrvineB
- NivolumabNational Cancer Institute (NCI)B
- SirexatamabLeap Therapeutics, Inc.B
Citation
Floatz Terminal. Monoclonal Antibody Neo-201 in Uterine Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/monoclonal-antibody-neo-201-uterine-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →